Navigation Links
Anadys Pharmaceuticals Reports Third Quarter 2008 Financial Results and Highlights
Date:10/23/2008

28,775 28,651 28,734 28,637

(1) Includes $- and $77 as additional research and development expense,

which represents an estimate of the net payable due to Novartis of

ANA975 research and development costs for the three months ended

September 30, 2008 and 2007, respectively. Includes ($47) and ($514)

as an offset in research and development expense, which represents an

estimate of the net reimbursement by Novartis of ANA975 research and

development costs for the nine months ended September 30, 2008 and

2007, respectively.

(2) Includes non-cash operating expenses of $738 and $1,392 determined in

accordance with Statement of Financial Accounts Standards No. 123(R),

"Share-Based Payment" (SFAS No. 123(R)) or approximately $0.03 and

$0.05 effect on basic and diluted net (loss) income per common share

for the three months ended September 30, 2008 and 2007, respectively.

Research and development expense and general and administrative

expense includes $326 and $412 of non-cash operating expenses

determined in accordance with SFAS No. 123(R) for the three months

ended September 30, 2008. Includes non-cash operating expenses of

$2,065 and $3,502 determined in accordance with SFAS No. 123(R) or

approximately $0.07 and $0.12 effect on basic and diluted net loss per

common share for the nine months ended September 30, 2008 and 2007,

respectively. Research and development expense and general and

administrative expense includes $949 and $1,116 of non-cash operating

expenses determined in accordance with SFAS No. 123(R) for the nine

months ended September 30, 2008.

Anadys Pharmaceuticals, Inc.

Condensed Consolidated Balance Sheets

(In thousands)


'/>"/>

SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
2. Anadys Pharmaceuticals to Report Third Quarter 2007 Financial Results
3. Anadys Pharmaceuticals to Present at the Acumen BioFin Rodman & Renshaw Healthcare Conference
4. Anadys Pharmaceuticals Reports Third Quarter 2007 Financial Results and Operational Highlights
5. Anadys Pharmaceuticals to Present at the Piper Jaffray Health Care Conference
6. Anadys Pharmaceuticals to Present at the JPMorgan Healthcare Conference
7. Anadys Pharmaceuticals to Present at the BIO CEO & Investor Conference
8. Anadys Pharmaceuticals to Report Fourth Quarter and Year-End 2007 Financial Results
9. Anadys Pharmaceuticals to Present at the Susquehanna SIGnificant Options in Healthcare Conference
10. Anadys Pharmaceuticals Commences Phase I Clinical Trial of ANA773 in Cancer Patients
11. Anadys Pharmaceuticals to Present at the Cowen and Company Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/26/2015)... Albany, NY (PRWEB) February 26, 2015 ... Market Research “Agricultural Biotechnology Market For Transgenic Crops (Corn, ... – Global Industry Analysis, Size, Share, Growth, Trends and ... valued at USD 15,300 million in 2012 and is ... at a CAGR of 9.5% from 2013 to 2019. ...
(Date:2/26/2015)... Regis Technologies announced new potent compound ... substances. , Regis Technologies is proud to announce the ... Suite (PCS) for 2015. , Regis is a contract ... in Morton Grove, Illinois. The PCS addition will provide ... to about one kilogram per batch. , Regis’ ...
(Date:2/26/2015)... , Feb. 26, 2015 Tauriga Sciences, Inc. ... company with interests in the natural wellness sector and ... today that its products will be featured at the ... Partners, 27 th Annual Growth Stock Conference on ... at 1 Ritz Carlton Drive, Dana Point ...
(Date:2/26/2015)... --  Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX ) ... 35 th Annual Health Care Conference on Tuesday, March ... .  Lexicon management will provide an overview of Lexicon,s ... the presentation will be available through Lexicon,s website at ... available at www.lexpharma.com until April 3, 2015. ...
Breaking Biology Technology:Global Agricultural Biotechnology Market is Expected to Reach USD 28,694.1 Million in 2019 : Transparency Market Research 2Global Agricultural Biotechnology Market is Expected to Reach USD 28,694.1 Million in 2019 : Transparency Market Research 3Regis Extends cGMP Services to Oncology Market 2SEC Compliance Featuring Products From Tauriga Sciences, Inc. at ROTH Capital Conference 2SEC Compliance Featuring Products From Tauriga Sciences, Inc. at ROTH Capital Conference 3SEC Compliance Featuring Products From Tauriga Sciences, Inc. at ROTH Capital Conference 4Lexicon To Present At The Cowen 35th Annual Health Care Conference 2
... governor and then secretary of the U.S. Department of ... with Alfacell Corporation. , ,Alfacell develops cancer theraputics and ... with the federal Food and Drug Administration for its ... New Jersy, but it has a local presence. , ...
... patched the Windows vulnerability that could allow malicious programs to ... security experts say the same part of Windows has even ... ,Giving in to pressure from users and security experts, some ... the company, Microsoft released the official patch days earlier than ...
... — QBI Life Sciences said it has ... formed partnerships with UW-Madison and the University of Helsinki, ... division of Quintessence Biosciences Inc. in Madison, will be ... harmful interactions between different drugs given to the same ...
Cached Biology Technology:
(Date:2/12/2015)... , Feb. 12, 2015   MedNet ... specializing in clinical study management systems, has recently ... , further distinguishing iMedNet ... Research Organizations (CROs) and healthcare consultants.  Building on ... prospective customer referrals and numerous co-marketing opportunities), MedNet,s ...
(Date:2/5/2015)... , 5. Februar 2015 ... spezialisiertes Logistikunternehmen und hat eine neue Marketingkampagne ... Logistikfirma (Clinical Logistics Organization – CLO) der ... Kampagne lautet First , mit Schwerpunkt ... Foto: http://photos.prnewswire.com/prnh/20150205/173753 Logo ...
(Date:2/5/2015)... SAN FRANCISCO , January 28, 2015 ... Camera Market Analysis, Size And Segment Forecasts To 2020 ... The global IR camera market is expected to reach ... study by Grand View Research, Inc. IR cameras help ... injuries, and are expected to witness surging demand in ...
Breaking Biology News(10 mins):MedNet Solutions Announces Key Enhancements To Its iMedNet Partner Program 2Marken startet Kampagne mit Patienten im Mittelpunkt 2Marken startet Kampagne mit Patienten im Mittelpunkt 3IR Camera Market Worth $5.10 Billion By 2020: Grand View Research, Inc. 2IR Camera Market Worth $5.10 Billion By 2020: Grand View Research, Inc. 3
... name, indicates a disease of the respiratory tract. But ... nervous system problems, according to an article in the ... online. , SARS, a potentially fatal illness caused by ... of 2003. The disease is usually transmitted by contact ...
... the most common childhood cancer is cured in about ... number was closer to five percent. In efforts to ... Children's Research Hospital, the University of Tennessee, and the ... play a role in the effectiveness of chemotherapy drugs. ...
... on earth, there were organic molecules that combined to ... first elements able to self-replicate. According to one of ... (RNA) chains, a molecule that is practically identical to ... cells of copying information stored in DNA and translating ...
Cached Biology News:New study shows SARS can infect brain tissue 2Genes linked to treatment resistance in children with leukemia 2Life's origins were easier than was thought 2
Request Info...
Mouse monoclonal [DJR3] to DcR1 (Biotin) ( Abpromise for all tested applications). entrezGeneID: 8794 SwissProtID: O14798...
...
Rabbit polyclonal to Quinolinic acid ( Abpromise for all tested applications). Antigen: Synthetic quinolinic acid conjugated to bovine serum albumin....
Biology Products: